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Pancreatic cancer (PanCa) has a dismal prognosis with five-year survival rates under 5%.  
PanCa is usally diagnosed at very late stages and even if diagnosed early, surgery is rarely 
an option. These factors contribute towards the bleak statistics for PanCa Chemo and 
radiation treatments having deleterious side-effects. There is therefore a clinical, unmet need 
for novel, targeted treatments with low morbidity in PanCa.  Gemzar® (gemcitabine-HCl) is 
an FDA (Food and Drug Administration) approved chemotherapeutic drug that has been 
used to treat PanCa. However, intrinsic and acquired chemoresistance to gemcitabine 
contribute to the poor prognosis of PanCa. A combination of Abraxane® (albumin-stabilized 
paclitaxel nano-formulation) with gemcitabine has shown survival benefits and has now 
become the first line treatment for PanCa. Desmoplasia is a fundamental characteristic of 
PanCa that contributes significantly to its chemoresistance, making drug delivery to PanCa 
cells difficult. Nanomedicines combining multiple drugs can be designed to overcome this 
hurdle. This project aims at developing a targeted nanomedicine by using a combination of 
gemcitabine and paclitaxel encapsulated in polymeric nanoparticles for the treatment of 
PanCa. Oil/ water emulsion technique was employed for the preparation of poly (lactic-co-
glycolic acid) (PLGA) nanoparticles encapsulating gemcitabine and paclitaxel.  Synthesis 
protocols yielded drug-loaded PLGA nanoparticles with an average diameter less than 200 
nm, with encapsulation efficiencies ranging from 40-70%. In vitro tests for cell viability 
studies using the MTT assay demonstrated lower cell viability in AsPC-1 cells when treated 
with these nano-formulations as compared to their free-drug counterparts. Current studies 
include conjugating drug-loaded PLGA-polyethylene glycol-Maleimide nanoparticles with 
transferrin peptide for targeted therapy, which is expected to prove more efficacious when 
tested for cell viability in vitro than its non-targeted formulations that have been obtained. 
These results therefore certify this nanotherapeutic approach as a potential therapy for 
PanCa.  
 
$ Presenting author, Aniket_Gad@student.uml.edu, (978)761-6836 
 * Corresponding author, prakash_rai@uml.edu  
 
 
